Current Management of Hairy Cell Leukemia

1st International Lymphoma Leukemia Myeloma (LLM) Congress Hairy cell leukemia (HCL) is a B-cell chronic lymphoproliferative disorder characterized by splenomegaly, pancytopenia, circulating lymphocytes displaying prominent cytoplasmic projections and reactive marrow fibrosis [1, 2]. HCL usually has an indolent disease course, and similarly to chronic lymphocytic leukemia , patients who are asymptomatic do not require therapy. However, treatment should be considered for symptomatic or cytopenic patients. Treatment is indicated for patients with significant neutropenia, thrombocytopenia, symptomatic splenomegaly, constitutional symptoms due to HCL or recurrent serious infections [3].